Extracellular vesicles as biomarkers in cancer immunotherapy
M Mathew, M Zade, N Mezghani, R Patel, Y Wang… - Cancers, 2020 - mdpi.com
Simple Summary Extracellular vesicles (EVs) are small particles found throughout the body.
EVs are released by living cells and contain cargo representing the cell of origin. In recent …
EVs are released by living cells and contain cargo representing the cell of origin. In recent …
Immunotherapy based on dendritic cell-targeted/-derived extracellular vesicles—a novel strategy for enhancement of the anti-tumor immune response
O Markov, A Oshchepkova, N Mironova - Frontiers in pharmacology, 2019 - frontiersin.org
Dendritic cell (DC)-based anti-tumor vaccines have great potential for the treatment of
cancer. To date, a large number of clinical trials involving DC-based vaccines have been …
cancer. To date, a large number of clinical trials involving DC-based vaccines have been …
Immunotherapeutic approaches for the treatment of colorectal cancer
EV Abakushina, YV Gelm, IA Pasova, AV Bazhin - Biochemistry (Moscow), 2019 - Springer
Colorectal cancer (CRC) originating from the cells of the colon or rectum has a high mortality
rate worldwide. Numerous attempts have been made to raise the overall survival rates of …
rate worldwide. Numerous attempts have been made to raise the overall survival rates of …
Extracellular vesicles after allogeneic hematopoietic cell transplantation: emerging role in post-transplant complications
Extracellular vesicles (EVs) play an important role in the cellular crosstalk by transferring
bioactive molecules through biological barriers from a cell to another, thus influencing …
bioactive molecules through biological barriers from a cell to another, thus influencing …
Dendritic Cell-Derived Artificial Microvesicles Inhibit RLS40 Lymphosarcoma Growth in Mice via Stimulation of Th1/Th17 Immune Response
OV Markov, AV Sen'kova, IS Mohamed, EV Shmendel… - Pharmaceutics, 2022 - mdpi.com
Cell-free antitumor vaccines represent a promising approach to immunotherapy of cancer.
Here, we compare the antitumor potential of cell-free vaccines based on microvesicles …
Here, we compare the antitumor potential of cell-free vaccines based on microvesicles …
Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy
AJ Hernández-Granados, MA Franco-Molina… - Research in veterinary …, 2018 - Elsevier
Whole tumor cell lysates consist of a mixture of tumor antigens and danger associated
molecular patterns (DAMPs) that can be used for dendritic cell maturation and consequently …
molecular patterns (DAMPs) that can be used for dendritic cell maturation and consequently …
Novel tumour antigens and the development of optimal vaccine design
VA Brentville, S Atabani, K Cook… - … advances in vaccines …, 2018 - journals.sagepub.com
The interplay between tumours and the immune system has long been known to involve
complex interactions between tumour cells, immune cells and the tumour microenvironment …
complex interactions between tumour cells, immune cells and the tumour microenvironment …
Personalized vaccination against ovarian cancer: what are the possibilities?
JL Tanyi, E George - Expert review of vaccines, 2018 - Taylor & Francis
The basis of immunology is the discrimination between self and nonself. All pathogens have
molecular signatures that can be recognized by the hostLs immune system and activate …
molecular signatures that can be recognized by the hostLs immune system and activate …
[HTML][HTML] Множественная миелома и вакцины на основе дендритных клеток
ИВ Грибкова, АА Завьялов - … . Фундаментальные исследования и …, 2021 - cyberleninka.ru
Несмотря на успехи, достигнутые в лечении множественной миеломы, у большинства
пациентов после его окончания сохраняется минимальная остаточная болезнь (МОБ …
пациентов после его окончания сохраняется минимальная остаточная болезнь (МОБ …
Multiple Myeloma and Dendritic Cell Vaccines
IV Gribkova, AA Zavyalov - old.bloodjournal.ru
Despite advances in the treatment of multiple myeloma, most of patients after its completion
retain minimal residual disease (MRD-positive status), which increases the risk of relapse …
retain minimal residual disease (MRD-positive status), which increases the risk of relapse …